Molecular epidemiology of Pseudomonas aeruginosa isolated from infected ICU patients: a French multicenter 2012-2013 study.


Journal

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297

Informations de publication

Date de publication:
May 2019
Historique:
received: 28 12 2018
accepted: 20 02 2019
pubmed: 4 3 2019
medline: 24 9 2019
entrez: 4 3 2019
Statut: ppublish

Résumé

Although Pseudomonas aeruginosa has a non-clonal epidemic population structure, recent studies have provided evidence of the existence of epidemic high-risk clones. The aim of this study was to assess the molecular epidemiology of P. aeruginosa isolates responsible for infections in French ICUs, regardless of resistance patterns. For a 1-year period, all non-duplicate P. aeruginosa isolated from bacteremia and pulmonary infections in ten adult ICUs of six French university hospitals were characterized by antimicrobial susceptibility testing and genotyping (MLST and PFGE). We identified β-lactamases with an extended spectrum phenotypically and by sequencing. The 104 isolates tested were distributed in 46 STs, of which 7 epidemic high-risk (EHR) clones over-represented: ST111, ST175, ST235, ST244, ST253, ST308, and ST395. Multidrug-resistant (MDR) isolates mostly clustered in these EHR clones, which frequently spread within hospitals. Only one ST233 isolate produced the carbapenemase VIM-2. PFGE analysis suggests frequent intra-hospital cross-transmission involving EHR clones. For ST395 and ST308, we also observed the progression from wild-type to MDR resistance pattern within the same PFGE pattern. Molecular epidemiology of P. aeruginosa in French ICUs is characterized by high clonal diversity notably among antimicrobial susceptible isolates and the over-representation of EHR clones, particularly within MDR isolates, even though multidrug resistance is not a constant inherent trait of EHR clones.

Identifiants

pubmed: 30826996
doi: 10.1007/s10096-019-03519-w
pii: 10.1007/s10096-019-03519-w
doi:

Substances chimiques

Anti-Bacterial Agents 0
DNA, Bacterial 0
beta-Lactamases EC 3.5.2.6

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

921-926

Subventions

Organisme : Ministère de l'Enseignement Supérieur, de la Recherche Scientifique et des Technologies de l'Information et de la Communication
ID : PHRC 2011

Références

Clin Infect Dis. 2000 Oct;31(4):E9-E14
pubmed: 11049805
J Clin Microbiol. 2004 Dec;42(12):5644-9
pubmed: 15583294
Antimicrob Agents Chemother. 2010 Aug;54(8):3512-5
pubmed: 20547814
J Clin Microbiol. 2011 Jun;49(6):2262-5
pubmed: 21450950
Front Microbiol. 2011 Apr 05;2:65
pubmed: 21747788
Antimicrob Agents Chemother. 2012 Dec;56(12):6349-57
pubmed: 23045355
Clin Microbiol Infect. 2014 Oct;20(10):O609-18
pubmed: 24422878
PLoS One. 2014 Sep 04;9(9):e107008
pubmed: 25187957
BMJ Open. 2014 Nov 04;4(11):e006278
pubmed: 25371418
J Antimicrob Chemother. 2015 May;70(5):1322-30
pubmed: 25583750
J Clin Microbiol. 2015 Apr;53(4):1395-8
pubmed: 25653397
J Clin Microbiol. 2015 Aug;53(8):2622-31
pubmed: 26041902
Drug Resist Updat. 2015 Jul-Aug;21-22:41-59
pubmed: 26304792
Sci Rep. 2016 May 20;6:26522
pubmed: 27198004
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7415-7423
pubmed: 27736752
Front Microbiol. 2016 Dec 05;7:1946
pubmed: 27994579
Clin Microbiol Infect. 2018 Mar;24(3):258-266
pubmed: 28648860
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 28993328
Microb Genom. 2017 Jun 8;3(10):e000129
pubmed: 29177088
Int J Med Microbiol. 2018 Mar;308(2):279-289
pubmed: 29276044
Infect Control Hosp Epidemiol. 2018 Feb;39(2):164-169
pubmed: 29417923

Auteurs

Céline Slekovec (C)

Hygiène Hospitalière, Centre Hospitalier Régional Universitaire, Besançon, France.
UMR 6249 Chrono-environnement, Université de Bourgogne-Franche-Comté, Besançon, France.

Jérôme Robert (J)

Centre d'immunologie et des maladies infectieuses-Paris, Cimi-Paris, INSERM, Laboratoire de Bactériologie-Hygiène, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Sorbonne Université, F-75013, Paris, France.

Nathalie van der Mee-Marquet (N)

Service de Bactériologie, Virologie et Hygiène, Centre Hospitalier Régional Universitaire, Tours, France.

Philippe Berthelot (P)

Hygiène hospitalière et maladies infectieuses, Centre Hospitalier Universitaire, Saint-Etienne, France.

Anne-Marie Rogues (AM)

Hygiène hospitalière, Centre Hospitalier Universitaire, INSERM U657, Université de Bordeaux, Bordeaux, France.

Véronique Derouin (V)

Bactériologie-Hygiène, AP-HP, Hôpitaux Universitaires Paris Sud- Clamart, Le Kremlin-Bicêtre, France.

Pascal Cholley (P)

Hygiène Hospitalière, Centre Hospitalier Régional Universitaire, Besançon, France.
UMR 6249 Chrono-environnement, Université de Bourgogne-Franche-Comté, Besançon, France.

Michelle Thouverez (M)

Hygiène Hospitalière, Centre Hospitalier Régional Universitaire, Besançon, France.
UMR 6249 Chrono-environnement, Université de Bourgogne-Franche-Comté, Besançon, France.

Didier Hocquet (D)

Hygiène Hospitalière, Centre Hospitalier Régional Universitaire, Besançon, France.
UMR 6249 Chrono-environnement, Université de Bourgogne-Franche-Comté, Besançon, France.
Centre d'immunologie et des maladies infectieuses-Paris, Cimi-Paris, INSERM, Laboratoire de Bactériologie-Hygiène, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Sorbonne Université, F-75013, Paris, France.

Xavier Bertrand (X)

Hygiène Hospitalière, Centre Hospitalier Régional Universitaire, Besançon, France. xbertrand@chu-besancon.fr.
UMR 6249 Chrono-environnement, Université de Bourgogne-Franche-Comté, Besançon, France. xbertrand@chu-besancon.fr.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH